 |
|
|
| |
Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2
Week 48 Results
|
| |
| |
EACS 2025, The 20th European AIDS Conference, 15-18 October 2025, Paris, France
Joseph Eron1*, Amy E. Colson2, Moti N. Ramgopal3, Arman Papadakis Sali4, Shan-Yu Liu4, Keith J. Dunn4, Todd L. Saretsky5, Cyril Llamoso5, Yohance Whiteside5, Lital Young5, Hadas Dvory-Sobol4, Devi SenGupta4, James Jarrett4, Gary I. Sinclair6
1University of North Carolina, Chapel Hill, NC, USA; 2Community Resource Initiative, Boston, MA, USA; 3Midway Immunology & Research Center, Fort Pierce, FL, USA; 4Gilead Sciences, Inc., Foster City, CA, USA; 5Merck & Co., Inc., Rahway, NJ, USA;6Prism Health North Texas, Dallas,TX, USA. *Presenting author
|
| |
|
|
|
|
|
